BTIG Research reissued their neutral rating on shares of Illumina Inc. (NASDAQ:ILMN) in a research report released on Wednesday morning.
A number of other research firms have also issued reports on ILMN. JPMorgan Chase & Co. raised their target price on shares of Illumina from $185.00 to $200.00 and gave the company an overweight rating in a research note on Wednesday, July 27th. Cantor Fitzgerald reissued a hold rating on shares of Illumina in a report on Wednesday, June 29th. Vetr downgraded shares of Illumina from a buy rating to a hold rating and set a $187.86 price target for the company. in a report on Monday. Argus increased their price target on shares of Illumina from $175.00 to $185.00 and gave the company a buy rating in a report on Monday, August 8th. Finally, Mizuho increased their price target on shares of Illumina from $138.00 to $148.00 and gave the company a neutral rating in a report on Wednesday, July 27th. Two investment analysts have rated the stock with a sell rating, fifteen have assigned a hold rating, nine have given a buy rating and one has issued a strong buy rating to the company’s stock. The company has a consensus rating of Hold and an average target price of $157.50.
Shares of Illumina (NASDAQ:ILMN) traded down 0.606% during midday trading on Wednesday, hitting $135.355. 383,418 shares of the company were exchanged. The stock’s 50-day moving average is $172.97 and its 200-day moving average is $156.29. The stock has a market cap of $19.84 billion, a PE ratio of 46.354 and a beta of 0.47. Illumina has a one year low of $127.10 and a one year high of $196.47.
Illumina (NASDAQ:ILMN) last posted its earnings results on Tuesday, July 26th. The life sciences company reported $0.86 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.73 by $0.13. Illumina had a net margin of 18.73% and a return on equity of 23.69%. The business had revenue of $600 million for the quarter, compared to analyst estimates of $31.91 million. During the same period last year, the business posted $0.80 EPS. Illumina’s revenue was up 11.3% compared to the same quarter last year. Equities research analysts anticipate that Illumina will post $3.53 EPS for the current year.
In other Illumina news, SVP Charles Dadswell sold 8,632 shares of the company’s stock in a transaction on Wednesday, July 27th. The shares were sold at an average price of $155.00, for a total value of $1,337,960.00. Following the transaction, the senior vice president now directly owns 40,248 shares in the company, valued at $6,238,440. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Jay T. Flatley sold 10,000 shares of the company’s stock in a transaction on Monday, July 18th. The shares were sold at an average price of $150.00, for a total transaction of $1,500,000.00. Following the completion of the transaction, the director now owns 498,061 shares in the company, valued at $74,709,150. The disclosure for this sale can be found here. Corporate insiders own 1.60% of the company’s stock.
Several institutional investors have recently added to or reduced their stakes in the stock. Patten & Patten Inc. TN bought a new position in Illumina during the third quarter valued at approximately $211,000. Fox Run Management L.L.C. bought a new position in Illumina during the third quarter valued at approximately $509,000. Terra Nova Asset Management LLC bought a new position in Illumina during the third quarter valued at approximately $620,000. Eagle Asset Management Inc. bought a new position in Illumina during the third quarter valued at approximately $22,528,000. Finally, Creative Planning increased its position in Illumina by 29.2% in the third quarter. Creative Planning now owns 26,275 shares of the life sciences company’s stock valued at $4,773,000 after buying an additional 5,932 shares in the last quarter. Hedge funds and other institutional investors own 95.22% of the company’s stock.
Illumina Company Profile